BUY Aurobindo Pharma — Ajit Mishra, 06 Apr 2026

byAjit Mishra, ReligareHorizon: 1–3 months6 Apr 2026via ET Now

Entry₹1,280Stated

Target₹1,500

Stop loss₹1,250-2.34% risk

Exit—No position was opened

ExpiredNA

Follow Ajit Mishra for new calls(44% target hit, 18 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Short-term call on AUROPHARMA

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 4:58 am IST

9 supporting4 neutral0 opposing

Supports the BUY call (9)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·3 Jul · 3d ago

Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma, has completed the acquisition of Lannett.

NSE · Acquisition·30 Jun · 6d ago

Aurobindo Pharma Ltd has announced the completion of an acquisition.

BSE · Company Update·25 Jun · 1w ago

Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm

NSE · Acquisition·25 Jun · 1w ago

Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.

NSE · Press Release·22 Jun · 2w ago

Neutral / worth noting (4)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Aurobindo Pharma — Ajit Mishra, Religare

AI Assessment